| Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation G Adeboyeje, G Sylwestrzak, JJ Barron, J White, A Rosenberg, J Abarca, ... Journal of managed care & specialty pharmacy 23 (9), 968-978, 2017 | 139 | 2017 |
| A comprehensive literature review and meta‐analysis of the prevalence of pan‐cancer BRCA mutations, homologous recombination repair gene mutations, and … C Shao, J Wan, FC Lam, H Tang, AR Marley, Y Song, C Miller, M Brown, ... Environmental and Molecular Mutagenesis 63 (6), 308-316, 2022 | 20 | 2022 |
| Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban B Charlton, G Adeboyeje, JJ Barron, D Grady, J Shin, RF Redberg PLoS One 13 (3), e0193912, 2018 | 14 | 2018 |
| Reducing overuse of colony-stimulating factors in patients with lung cancer receiving chemotherapy: Evidence from a decision support–enabled program G Adeboyeje, A Agiro, J Malin, MJ Fisch, A DeVries Journal of oncology practice 13 (4), e337-e345, 2017 | 11 | 2017 |
| Comparative effectiveness and safety of anticoagulant therapy with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation G Adeboyeje, G Sylwestrzak, J White, A Rosenberg, J Abarca, G Crawford, ... Circulation: Cardiovascular Quality and Outcomes 9 (suppl_2), A2-A2, 2016 | 11 | 2016 |
| A Systematic Review and Meta‐Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer C Shao, MS Chang, FC Lam, AR Marley, H Tang, Y Song, C Miller, ... Journal of Oncology 2022 (1), 5830475, 2022 | 7 | 2022 |
| Barriers to next-generation sequencing despite increased utilization: US physician survey results. A Kaminski, EA Szamreta, R Shah, N Ning, J Aggarwal, A Hussain, ... Journal of Clinical Oncology 39 (15_suppl), e18754-e18754, 2021 | 7 | 2021 |
| Association between time to first subsequent therapy (TFST) and overall survival (OS) in previously untreated patients with ovarian cancer (OC): A SEER Medicare database analysis. K Desai, D Muston, G Adeboyeje, MJ Monberg Journal of Clinical Oncology 37 (15_suppl), e17095-e17095, 2019 | 3 | 2019 |
| Trends in BRCA testing among patients diagnosed with breast cancer-a retrospective analysis of a United States commercial claims database from the PRIOR-1 study S Corman, H Kale, P Shah, G Adeboyeje Cancer Research 81 (4 Supplement), PS7-78-PS7-78, 2021 | 2 | 2021 |
| Use of BRCA testing among patients diagnosed with pancreatic cancer: Analysis of commercial claims database in the United States. G Adeboyeje, P Shah, S Corman, H Kale Journal of Clinical Oncology 38 (29_suppl), 291-291, 2020 | 2 | 2020 |
| Length of hospital stay and all-cause mortality among adults with atrial fibrillation hospitalized for bleeding during treatment with warfarin, dabigatran, or rivaroxaban B Charlton, G Adeboyeje, JJ Barron, D Grady, J Shin, R Redberg Circulation 132 (suppl_3), A11583-A11583, 2015 | 2 | 2015 |
| Trends in The Use of Comprehensive Genomic Profiling Among Older Patients With Advanced Cancer From 2018 to 2020 in the United States: Findings From the SEQUENCE Study M Chase, Y Xu, EO Caplan, N Myer, S Sheth, BT Suehs, G Adeboyeje Journal of the National Comprehensive Cancer Network 20 (3.5), CGE22-096 …, 2022 | 1* | 2022 |
| Overall survival by BRCA and ATM mutation status in patients with metastatic pancreatic cancer: Findings from the PRIOR-2 study G Adeboyeje, MI Sierra, A Bartels, M Field, S Jhamb, A Buikema, S Joo Annals of Oncology 32, S1088, 2021 | 1 | 2021 |
| Survey study of barriers to evidence-based decision-making in oncology care using next-generation sequencing. EA Szamreta, A Kaminski, R Shah, N Ning, J Aggarwal, A Hussain, ... Journal of Clinical Oncology 39 (15_suppl), e18757-e18757, 2021 | 1 | 2021 |
| A comprehensive literature review and meta-analysis on prognostic value of BRCAm, HRRm and HRD+ across tumor types. C Shao, A Marley, H Tang, J Wan, C Miller, M Brown, Y Song, J Han, ... Journal of Clinical Oncology 39 (15_suppl), 3125-3125, 2021 | 1 | 2021 |
| Clinical effectiveness outcomes and healthcare resource utilization of patients diagnosed with small-cell lung cancer J Lin, S Gautam, N Hu, G Adeboyeje, S Kachroo Future Oncology 17 (4), 443-453, 2021 | 1 | 2021 |
| Economic burden associated with early progression in ovarian cancer G Adeboyeje, K Desai, S Iqbal, MJ Monberg Gynecologic Oncology 159, 148, 2020 | 1 | 2020 |
| Current Utilization of Genomic Testing and Barriers to Optimal Patient Care: A Targeted Literature Review A Kaminski, J Aggarwal, G Adeboyeje Journal of the National Comprehensive Cancer Network 18 (3.5), HSR20-090 …, 2020 | 1 | 2020 |
| Real-World Utilization and Coding Variability in Medical Claims for Next-Generation Sequencing (NGS)-Based Diagnostic Tests Among Cancer Patients in the US K Desai, G Hooker, G Adeboyeje, S Kachroo, SS Sen Journal of the National Comprehensive Cancer Network 18 (3.5), HSR20-083 …, 2020 | 1* | 2020 |
| Survival associated with first-line bevacizumab maintenance therapy among older patients with ovarian cancer: findings from the VIERA study G Adeboyeje, M Monberg, S Iqbal, J He, K Desai International Journal of Gynecologic Cancer 29 (Suppl 4), A427-A428, 2019 | 1 | 2019 |